1. .. , ,
2. .. ...,
3. ..- .
4. .. - -
5. .. .
6. .. -
7. ..
17. : .
18. :
. , , ..
19. : , ,
20. :
1. , . .. , 2012.
2. , .., 2011
3. . .2- / . .. . - .: -, 2010. - 738 .
4. .., .., .. ACR/EULAR 2010 //- , 2011, 1, 10-15.
5. . , ., . . / . .. , 2011.
6. Smolen J.S., Landewe R., Breedveld F.C. et al. EULAR recommendations for the management of rheumatoid arthritis withsynthetic and biological disease-modifying antirheumatic drugs. AnnRheumDis, 2010; 69:96475.
7. .. : ( -6). 2010;5:6471.
8. . . 2- ., .., 2010
9. .. () . - 2009; 3(.):1835.
10. Van Vollenhoven R.F. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009;5:53141.
11. .., .., .. . . . .: -, 2009.
12. : / . .. , .. . - .: -, 2008. - 720 .
13. Emery P., Keystone E., Tony H.-P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti- TNF biologics: results from a 24-week multicenter randomized placebo-controlled trial.
14. .. - , 2008
15. AnnRheumDis 2008;67:151623.
16. : ompendium/ .., .., .., .. .; . . .. , .. . .: , 2007. 448.
|
|
17. Nam J.L., Wintrop K.L., van Vollenhoven R.F. et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systemic literature rewires informing the EULAR recommendationsfor the management of RA.
18. .. () . - , 2009; 3(.):1835.
19. .., .. - , 2007.
20. .. - , 2005.
21. . . . .. - -. , 2001.- .116
22. Paul Emery et al. , , , , ARTHRITIS & RHEUMATISM, 60, 8, 2009, . 22722283, DOI 10.1002/art.24638
23. Mark C. Genovese et al. : GO-FORWARD, J Rheumatol 15 2012 , DOI: 10.3899/jrheum.111195
24. Josef S Smolen ( GO-AFTER): , , , - III, Lancet 2009; 374: 21021